Anti-PDE9A antibody

Anti-PDE9A antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit polyclonal to PDE9A

ELISA, WB

Human PDE9A

FLJ90181 antibody; HSPDE9A2 antibody; PDE9A antibody; Pde9a antibody; PDE9A1 antibody; HSPDE9A2 antibody; PDE9A1 antibody

Rabbit IgG

Produced in rabbits immunized with purified, recombinant Human PDE9A (rh PDE9A; O76083-2; Pro181-Lys506). PDE9A specific IgG was purified by Human PDE9A affinity chromatography.

Polyclonal

0.2 μm filtered solution in PBS

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, also known as PDE9A, is a member of the cyclic nucleotide phosphodiesterase family and PDE9 subfamily. PDE9A is expressed in all tissues examined (testis, brain, small intestine, skeletal muscle, heart, lung, thymus, spleen, placenta, kidney, liver, pancreas, ovary and prostate) except blood. Highest levels of PDE9A is in brain, heart, kidney, spleen, prostate and colon. Isoform PDE9A12 is found in prostate. PDE9A mRNA is widely distributed throughout the rat and mouse brain, with the highest expression observed in cerebellar Purkinje cells. PDE9A is the only cGMP-specific PDE with significant expression in the forebrain, and as such is likely to play an important role in NO-cGMP signaling. PDE9A is highly conserved between species and is widely distributed throughout the rodent brain. PDE9A is probably involved in maintenance of low cGMP levels in cells and might play an important role in a variety of brain functions involving cGMP-mediated signal transduction. PDE9A hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. PDE9A represents a novel drug target worthy of further study.

• Andreeva, SG. et al., 2001,J Neurosci. 21 (22):9068-76.
• van Staveren,WC. et al., 2002, J Neurocytol. 31 (8-9):729-41.
• Almeida,CB. et al., 2008, Br J Haematol. 142 (5):836-44.
• Kruse,L.S. et al., 2009, Brain Res. 1281 :25-34.